Atectura Breezhaler

Country: Нови Зеланд

Језик: Енглески

Извор: Medsafe (Medicines Safety Authority)

Активни састојак:

Indacaterol acetate 173ug equivalent to indacaterol 150µg; Mometasone furoate 160ug

Доступно од:

Novartis New Zealand Ltd

Фармацеутски облик:

Powder filled inhalation capsule

Састав:

Active: Indacaterol acetate 173ug equivalent to indacaterol 150µg Mometasone furoate 160ug Excipient: Gelatin Printing ink, grey Lactose monohydrate

Тип рецептора:

Prescription

Терапеутске индикације:

Atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate: · patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or · patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists.

Резиме производа:

Package - Contents - Shelf Life: Blister pack, PA/Al/PVC/Al-polyamide-aluminium foil-polyvinylchloride/aluminium foil + inhaler - 10 capsules - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Blister pack, PA/Al/PVC/Al-polyamide-aluminium foil-polyvinylchloride/aluminium foil + inhaler - 30 capsules - 24 months from date of manufacture stored at or below 25°C protect from light and moisture

Датум одобрења:

2020-10-21